ADAGIO THERAPEUTICS INC (ADGI) Stock Price, Forecast & Analysis
NASDAQ:ADGI • US00534A1025
ADGI Key Statistics, Chart & Performance
The current stock price of ADGI is 4.64 USD. In the past month the price increased by 16.29%. In the past year, price decreased by -90.98%.
ADGI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ADGI. When comparing the yearly performance of all stocks, ADGI turns out to be only a medium performer in the overall market: it outperformed 60.44% of all stocks.
ADGI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADGI. While ADGI seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADGI Financial Highlights
Over the last trailing twelve months ADGI reported a non-GAAP Earnings per Share(EPS) of -3.15. The EPS decreased by -74.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.89% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ADGI Forecast & Estimates
9 analysts have analysed ADGI and the average price target is 3.91 USD. This implies a price decrease of -15.73% is expected in the next year compared to the current price of 4.64.
ADGI Ownership
ADGI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 397.325B | ||
| AMGN | AMGEN INC | 16.84 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.8 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.94 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.16 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.91 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.1 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADGI
Company Profile
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The firm has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.
Company Info
ADAGIO THERAPEUTICS INC
1601 Trapelo Road, Suite 178
Waltham MASSACHUSETTS US
Employees: 101
Phone: 17818190080.0
ADAGIO THERAPEUTICS INC / ADGI FAQ
Can you describe the business of ADAGIO THERAPEUTICS INC?
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The firm has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.
What is the current price of ADGI stock?
The current stock price of ADGI is 4.64 USD. The price increased by 0.87% in the last trading session.
What is the dividend status of ADAGIO THERAPEUTICS INC?
ADGI does not pay a dividend.
How is the ChartMill rating for ADAGIO THERAPEUTICS INC?
ADGI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ADAGIO THERAPEUTICS INC?
ADAGIO THERAPEUTICS INC (ADGI) operates in the Health Care sector and the Biotechnology industry.
Should I buy ADGI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADGI.